# US 2023/0346920 A1 · Vaccines against viral pathogens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0346920 A1
- Document ID: US20230346920A1
- Status: Published application
- Kind: A1
- Application number: 17/997,886
- Filed: 2021-05-04
- Published: 2023-11-02
- Earliest claimed: 2020-05-04
- Assignees: Hexamer Therapeutics, Inc.
- Applicants: Hexamer Therapeutics, Inc.
- Inventors: Keith Douglas Miller; Robert Bogden
- Web page: https://patentgrep.com/patent/US20230346920A1

## CPC

- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K 39/12: Viral antigens
- A61K 39/385: Haptens or antigens, bound to carriers
- A61P 31/14: for RNA viruses
- C07K 7/06: having 5 to 11 amino acids
- C07K 14/005: from viruses
- A61K 2039/51: {comprising whole cells, viruses or DNA/RNA}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/555: {characterised by a specific combination antigen/adjuvant}
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/575: {humoral response}
- A61K 2039/6012: {Haptens, e.g. di- or trinitrophenyl (DNP, TNP)}
- C07K 14/165: Coronaviridae, e.g. avian infectious bronchitis virus
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20071: Demonstrated in vivo effect
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure describes a unique viral peptide (VP) vaccine for preventing or treating viral diseases. The vaccine is produced synthetically and includes no production steps in biological cells (e.g. E. coli, CHO cells, yeast cells) that would require subsequent endotoxin assays/removal or viral clearance procedures. The hC peptide is synthesized separately from the VP, and following self-assembly of the hC, the VP is covalently coupled to form the VP-hC conjugate which can serve as a vaccine for preventing or treating viral diseases. The hC includes heptad repeats following a specific pattern. Optionally, the VP-hC conjugate further includes one or more T-cell epitopes at the N- and/or C-terminus of the one or more amphipathic alpha-helices. The present disclosure also describes compositions comprising immunogenic compositions including VP-hC conjugate.

## Claims

### Claim 1

A viral peptide (VP) conjugate (VP-hC) or a VP oligomer (VPhC) comprising one or more viral peptides (VPs) covalently attached to a hapten carrier (hC), the hC comprising a monomeric peptide comprising the following amino acid sequence:
(hwxhxyz)n (SEQ ID NO: 2),
wherein
h is a hydrophobic or non-polar residue;
w is a positively charged, negatively charged, polar uncharged, or non-polar aliphatic residue;
x is a negatively charged, positively charged, non-polar aliphatic, or polar uncharged residue;
y is a residue for epitope coupling;
z is a negatively charged, positively charged, polar uncharged, or non-polar aliphatic residue; and
n is an integer greater than 1; and
wherein the VP conjugate comprises one or more VPs conjugated to the hC; and
wherein the VP oligomer comprises one or more VP incorporated into the hC.

### Claim 2 (depends on 1)

The VP conjugate or VP oligomer of claim 1, wherein the monomeric peptide comprises amino acid sequence SEQ ID NO: 2, wherein
h is I, L, V, F, W, Y, M, G, or A;
w is G, R, A, N, Q, H, S, D, E, K, or T;
x is R, S, N, Q, A, G, T, D, E, K, H, or C;
y is K, H, C, D, E, R, W, Y, Q, N, or a non-natural amino acid or molecule containing reactive groups amenable to covalent coupling;
z is A, D, H, S, E, R, N, Q, K, or G; and
n is 2 to 10.

### Claim 3 (depends on 1)

The VP conjugate or VP oligomer of claim 1, wherein the monomeric peptide comprises amino acid sequence SEQ ID NO: 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31.

### Claim 4 (depends on 1)

The VP conjugate or VP oligomer of claim 1, wherein the monomeric peptide forms a dimer, trimer, tetramer, pentamer, hexamer, heptamer, octamer, nanomer, or decamer.

### Claim 5 (depends on 1)

The VP conjugate or VP oligomer of claim 1, wherein the one or more VPs are obtained from a Coronavirus, an Influenza virus, a Respiratory Syncytial virus (RSV), Human Papillomavirus (HPV), Dengue virus, Yellow Fever virus (YFV), or West Nile virus (WNV) and optionally, wherein the one or more VPs are obtained from a SARS-CoV-2 virus.

### Claim 6 (depends on 5)

The VP conjugate or VP oligomer of claim 5, wherein the one or more VPs comprise one or more S peptides of the spike glycoprotein or the membrane protein (M) of a SARS-CoV-2 virus, and optionally, wherein the one or more S peptides comprise S1, S2, S3, S4, S5, and/or S6, and the membrane peptide comprises M1.

### Claim 7 (depends on 6)

The VP conjugate or VP oligomer of claim 6, wherein the one or more VPs comprise amino acid sequence SEQ ID NO: 136, 120, 132, 119, 118, 117, and/or 130.

### Claim 8 (depends on 1)

The VP conjugate or VP oligomer of claim 1, wherein the one or more VP comprise a modified VP, the modified VP comprising a modified amino acid sequence, and optionally, wherein one or more cysteines (C) is substituted with serine (S), or wherein the modified VP comprises amino acid sequence SEQ ID NO: 139 or 140.

### Claim 9 (depends on 7)

The VP conjugate or VP oligomer of claim 7, wherein the one or more VPs comprise additional amino acids at its N- and/or C-terminus, the additional amino acids being V (valine) and/or DDEDC (SEQ ID NO: 116), and optionally, wherein the one or more VPs comprise amino acid sequence SEQ ID NO: 73, 57, 69, 115, 55, 54, and/or 67.

### Claim 10 (depends on 9)

The VP conjugate or VP oligomer of claim 9, wherein the one or more VPs further comprising a protecting group at its N- and/or C-terminus, and optionally, wherein the protecting group comprises an acetyl group and/or an amide group.

### Claim 11 (depends on 1)

The VP conjugate or VP oligomer of claim 1, wherein the VP conjugate or VP oligomer comprises two or more VPs from different sources or strains of SARS-CoV-2.

### Claim 12 (depends on 1)

The VP conjugate or VP oligomer of claim 1, wherein the one or more VPs are conjugated to the hC through the y residue on the monomeric peptide.

### Claim 13 (depends on 1)

The VP conjugate or VP oligomer of claim 1, wherein the one or more VPs or the monomeric peptide further comprises one or more immunomodulators or additional haptens, one or more spacers or linkers between the hapten or immunomodulator and the monomeric peptide, and/or one or more residues for correct processing of the one or more T-cell epitopes.

### Claim 14 (depends on 13)

The VP conjugate or VP oligomer of claim 13, wherein the one or more haptens or immunomodulators comprise one or more additional VPs, one or more T-cell epitopes, and/or one or more B-cell epitopes.

### Claim 15 (depends on 1)

The VP conjugate or VP oligomer of claim 1, wherein the VP conjugate or VP oligomer comprises a hC comprising amino acid sequence SEQ ID NO: 112 or 113.

### Claim 16 (depends on 1)

A pharmaceutical composition comprising the VP conjugate or VP oligomer of claim 1 and a pharmaceutically acceptable excipient, and optionally, wherein the excipient comprises MPL A.

### Claim 17 (depends on 16)

A method of treating a subject having a viral disease or infection and/or preventing a subject from developing a viral disease or infection, wherein the method comprises administering to the subject, an effective amount of the composition of claim 16, wherein the VP induces an immune response in the subject, thereby treating the subject having the viral disease or infection or preventing the subject from developing the viral disease or infection, and optionally the viral disease or infection is caused by SARS-CoV-2.

### Claim 18 (depends on 17)

The method of claim 17, wherein the subject is a mammal, and optionally the mammal is a human.

### Claim 19 (depends on 1)

A method of enhancing the immunogenicity of a VP, wherein the method comprises:
(a) obtaining a monomeric peptide of the VP conjugate of claim 1,
allowing the monomeric peptide to self-assemble into a hC, and
conjugating a VP to the hC to obtain a VP-hC conjugate;
or
(b) synthesizing a VP monomeric peptide (VPMP), wherein the VPMP comprises a monomeric peptide (MP) of the VP oligomer of claim 1 and a VP, and allowing the VPMP to self-assemble into a VPhC oligomer.

### Claim 20 (depends on 1)

A method of preparing a VP therapeutic or vaccine, wherein the method comprises:
(a) obtaining a monomeric peptide of the VP conjugate or VP oligomer of claim 1,
allowing the monomeric peptide to self-assemble into a hC, and
conjugating a VP to the hC to obtain a VP-hC conjugate, thereby obtaining a VP therapeutic or vaccine;
or
(b) synthesizing a VP monomeric peptide (VPMP), wherein the VPMP comprises a monomeric peptide of claim 1 and a VP of claim 1, and
allowing the VPMP to self-assemble into a VPhC oligomer, thereby obtaining a VP therapeutic or vaccine.

### Claim 21 (depends on 19)

The method of claim 19, wherein the method further comprises the monomeric peptide self-assembling into a hexameric hC.

### Claim 22

A peptide immunogen comprising amino acid SEQ ID NO: 73, 57, 69, 115, 55, 54, or 67 and optionally, wherein the peptide immunogen comprises amino acid SEQ ID NO: 73, 55, or 54.

### Claim 23 (depends on 22)

The peptide immunogen of claim 22, wherein the N-terminus and/or the C-terminus of the peptide immunogen comprise a protecting group, and optionally, wherein the protecting group of the N-terminus comprises an acetyl group and the protecting group of the C-terminus comprises an amide group.

### Claim 24

A peptide scaffold comprising amino acid SEQ ID NO: 112 or 113.

### Claim 25 (depends on 24)

The peptide scaffold of claim 24, wherein the N-terminus and/or the C-terminus of the peptide scaffold comprise a protecting group, and optionally, wherein the protecting group of the N-terminus comprises an acetyl group and the protecting group of the C-terminus comprises an amide group.

### Claim 26 (depends on 22)

A composition comprising one or more peptide immunogens of claim 22 and a peptide scaffold comprising amino acid SEQ ID NO: 112 or 113.

### Claim 27 (depends on 26)

The composition of claim 26, wherein the one or more peptide immunogens are attached to the peptide scaffold.

### Claim 28 (depends on 26)

The composition of claim 26, wherein the one or more peptide immunogens are not attached to the peptide scaffold.

### Claim 29 (depends on 20)

The method of claim 20, wherein the method further comprises the monomeric peptide self-assembling into a hexameric hC.
